In line with the aforementioned observations, cabozantinib (XL-184), a multi-target tyrosine kinase inhibitor suppressing c-Met activation, maintained stable disease in 8 out of 12 patients with relapsed and/or refractory MM in another clinical phase IB study[48]. Here, MET is linked to Miyoshi myopathy.